Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „golimumab“
Suchtreffer
Begriffe & Kennungen
Gobivaz · 4.8 · Injection site reactions In the controlled periods of pivotal trials, 5.4% of golimumab-treated patients had i
Eintrag öffnenGobivaz · 4.8 · Injection site reactions In the controlled periods of pivotal trials, 5.4% of golimumab-treated patients had i
Eintrag öffnenGobivaz · 4.8 · Injection site reactions In the controlled periods of pivotal trials, 5.4% of golimumab-treated patients had i
Eintrag öffnenGobivaz · 4.8 · Injection site reactions In the controlled periods of pivotal trials, 5.4% of golimumab-treated patients had i
Eintrag öffnenGobivaz · 4.8 · Malignancies Lymphoma The incidence of lymphoma in golimumab-treated patients during the pivotal trials was hi
Eintrag öffnenGobivaz · 4.8 · Malignancies Lymphoma The incidence of lymphoma in golimumab-treated patients during the pivotal trials was hi
Eintrag öffnenGobivaz · 4.8 · Malignancies Lymphoma The incidence of lymphoma in golimumab-treated patients during the pivotal trials was hi
Eintrag öffnenGobivaz · 4.8 · Malignancies Lymphoma The incidence of lymphoma in golimumab-treated patients during the pivotal trials was hi
Eintrag öffnenGobivaz · 4.8 · Paediatric population Polyarticular juvenile idiopathic arthritis The safety of golimumab has been studied in
Eintrag öffnenGobivaz · 4.8 · Paediatric population Polyarticular juvenile idiopathic arthritis The safety of golimumab has been studied in
Eintrag öffnenGobivaz · 4.8 · Paediatric population Ulcerative colitis The safety of golimumab has been studied in a Phase III study of 69 p
Eintrag öffnenGobivaz · 4.8 · Ulcerative colitis The safety of golimumab has been studied in a Phase III study of 69 patients from 4 to 17 y
Eintrag öffnenGobivaz · 4.8 · non-infectious fatal hepatitis with jaundice. The role of golimumab as a contributing or aggravation factor ca
Eintrag öffnenGobivaz · 4.8 · non-infectious fatal hepatitis with jaundice. The role of golimumab as a contributing or aggravation factor ca
Eintrag öffnenGotenfia · 4.5 · Concurrent use with other biological therapeutics The combination of golimumab with other biological therapeut
Eintrag öffnenGotenfia · 4.5 · Concurrent use with other biological therapeutics The combination of golimumab with other biological therapeut
Eintrag öffnenGotenfia · 4.5 · Live vaccines/therapeutic infectious agents Live vaccines should not be given concurrently with golimumab (see
Eintrag öffnenGotenfia · 4.5 · Live vaccines/therapeutic infectious agents Live vaccines should not be given concurrently with golimumab (see
Eintrag öffnenGotenfia · 4.5 · Methotrexate Although concomitant use of MTX results in higher steady-state trough concentrations of golimumab
Eintrag öffnenGotenfia · 4.5 · Methotrexate Although concomitant use of MTX results in higher steady-state trough concentrations of golimumab
Eintrag öffnen